001package org.hl7.fhir.r4.model.codesystems;
002
003/*
004  Copyright (c) 2011+, HL7, Inc.
005  All rights reserved.
006  
007  Redistribution and use in source and binary forms, with or without modification, 
008  are permitted provided that the following conditions are met:
009  
010   * Redistributions of source code must retain the above copyright notice, this 
011     list of conditions and the following disclaimer.
012   * Redistributions in binary form must reproduce the above copyright notice, 
013     this list of conditions and the following disclaimer in the documentation 
014     and/or other materials provided with the distribution.
015   * Neither the name of HL7 nor the names of its contributors may be used to 
016     endorse or promote products derived from this software without specific 
017     prior written permission.
018  
019  THIS SOFTWARE IS PROVIDED BY THE COPYRIGHT HOLDERS AND CONTRIBUTORS "AS IS" AND 
020  ANY EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, THE IMPLIED 
021  WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE ARE DISCLAIMED. 
022  IN NO EVENT SHALL THE COPYRIGHT HOLDER OR CONTRIBUTORS BE LIABLE FOR ANY DIRECT, 
023  INDIRECT, INCIDENTAL, SPECIAL, EXEMPLARY, OR CONSEQUENTIAL DAMAGES (INCLUDING, BUT 
024  NOT LIMITED TO, PROCUREMENT OF SUBSTITUTE GOODS OR SERVICES; LOSS OF USE, DATA, OR 
025  PROFITS; OR BUSINESS INTERRUPTION) HOWEVER CAUSED AND ON ANY THEORY OF LIABILITY, 
026  WHETHER IN CONTRACT, STRICT LIABILITY, OR TORT (INCLUDING NEGLIGENCE OR OTHERWISE) 
027  ARISING IN ANY WAY OUT OF THE USE OF THIS SOFTWARE, EVEN IF ADVISED OF THE 
028  POSSIBILITY OF SUCH DAMAGE.
029  
030*/
031
032// Generated on Wed, Jan 30, 2019 16:19-0500 for FHIR v4.0.0
033
034import org.hl7.fhir.exceptions.FHIRException;
035
036public enum V3ObservationInterpretation {
037
038  /**
039   * Codes that specify interpretation of genetic analysis, such as "positive",
040   * "negative", "carrier", "responsive", etc.
041   */
042  _GENETICOBSERVATIONINTERPRETATION,
043  /**
044   * The patient is considered as carrier based on the testing results. A carrier
045   * is an individual who carries an altered form of a gene which can lead to
046   * having a child or offspring in future generations with a genetic disorder.
047   */
048  CAR,
049  /**
050   * The patient is considered as carrier based on the testing results. A carrier
051   * is an individual who carries an altered form of a gene which can lead to
052   * having a child or offspring in future generations with a genetic disorder.
053   * 
054   * 
055   * 
056   * Deprecation Comment: This code is currently the same string as the print name
057   * for this concept and is inconsistent with the conventions being used for the
058   * other codes in the coding system, as it is a full word with initial
059   * capitalization, rather than an all upper case mnemonic. The recommendation
060   * from OO is to deprecate the code "Carrier" and to add "CAR" as the new active
061   * code representation for this concept.
062   */
063  CARRIER,
064  /**
065   * Interpretations of change of quantity and/or severity. At most one of B or W
066   * and one of U or D allowed.
067   */
068  _OBSERVATIONINTERPRETATIONCHANGE,
069  /**
070   * The current result or observation value has improved compared to the previous
071   * result or observation value (the change is significant as defined in the
072   * respective test procedure).
073   * 
074   * [Note: This can be applied to quantitative or qualitative observations.]
075   */
076  B,
077  /**
078   * The current result has decreased from the previous result for a quantitative
079   * observation (the change is significant as defined in the respective test
080   * procedure).
081   */
082  D,
083  /**
084   * The current result has increased from the previous result for a quantitative
085   * observation (the change is significant as defined in the respective test
086   * procedure).
087   */
088  U,
089  /**
090   * The current result or observation value has degraded compared to the previous
091   * result or observation value (the change is significant as defined in the
092   * respective test procedure).
093   * 
094   * [Note: This can be applied to quantitative or qualitative observations.]
095   */
096  W,
097  /**
098   * Technical exceptions resulting in the inability to provide an interpretation.
099   * At most one allowed. Does not imply normality or severity.
100   */
101  _OBSERVATIONINTERPRETATIONEXCEPTIONS,
102  /**
103   * The result is below the minimum detection limit (the test procedure or
104   * equipment is the limiting factor).
105   * 
106   * Synonyms: Below analytical limit, low off scale.
107   */
108  LESS_THAN,
109  /**
110   * The result is above the maximum quantifiable limit (the test procedure or
111   * equipment is the limiting factor).
112   * 
113   * Synonyms: Above analytical limit, high off scale.
114   */
115  GREATER_THAN,
116  /**
117   * A valid result cannot be obtained for the specified component / analyte due
118   * to the presence of anti-complementary substances in the sample.
119   * 
120   * 
121   * 
122   * Deprecation Comment: This code is being deprecated to match the status in V2
123   * Table 0078 "Interpretation Codes.
124   */
125  AC,
126  /**
127   * There is insufficient evidence that the species in question is a good target
128   * for therapy with the drug. A categorical interpretation is not possible.
129   * 
130   * [Note: A MIC with "IE" and/or a comment may be reported (without an
131   * accompanying S, I or R-categorization).]
132   */
133  IE,
134  /**
135   * A result cannot be considered valid for the specified component / analyte or
136   * organism due to failure in the quality control testing component.
137   * 
138   * 
139   * 
140   * Deprecation Comment: This code is being deprecated to match the status in V2
141   * Table 0078 "Interpretation Codes.
142   */
143  QCF,
144  /**
145   * A valid result cannot be obtained for the specified organism or cell line due
146   * to the presence of cytotoxic substances in the sample or culture.
147   * 
148   * 
149   * 
150   * Deprecation Comment: This code is being deprecated to match the status in V2
151   * Table 0078 "Interpretation Codes.
152   */
153  TOX,
154  /**
155   * Interpretation of normality or degree of abnormality (including critical or
156   * "alert" level). Concepts in this category are mutually exclusive, i.e., at
157   * most one is allowed.
158   */
159  _OBSERVATIONINTERPRETATIONNORMALITY,
160  /**
161   * The result or observation value is outside the reference range or expected
162   * norm (as defined for the respective test procedure).
163   * 
164   * [Note: Typically applies to non-numeric results.]
165   */
166  A,
167  /**
168   * The result or observation value is outside a reference range or expected norm
169   * at a level at which immediate action should be considered for patient safety
170   * (as defined for the respective test procedure).
171   * 
172   * [Note: Typically applies to non-numeric results. Analogous to critical/panic
173   * limits for numeric results.]
174   */
175  AA,
176  /**
177   * The result for a quantitative observation is above a reference level at which
178   * immediate action should be considered for patient safety (as defined for the
179   * respective test procedure).
180   * 
181   * Synonym: Above upper panic limits.
182   */
183  HH,
184  /**
185   * The result for a quantitative observation is below a reference level at which
186   * immediate action should be considered for patient safety (as defined for the
187   * respective test procedure).
188   * 
189   * Synonym: Below lower panic limits.
190   */
191  LL,
192  /**
193   * The result for a quantitative observation is above the upper limit of the
194   * reference range (as defined for the respective test procedure).
195   * 
196   * Synonym: Above high normal
197   */
198  H,
199  /**
200   * A test result that is significantly higher than the reference (normal) or
201   * therapeutic interval, but has not reached the critically high value and might
202   * need special attention, as defined by the laboratory or the clinician.[Note:
203   * This level is situated between 'H' and 'HH'.]
204   * 
205   * 
206   * Deprecation Comment: The code 'H>' is being deprecated in order to align with
207   * the use of the code 'HU' for "Very high" in V2 Table 0078 "Interpretation
208   * Codes".
209   * 
210   * [Note: The use of code 'H>' is non-preferred, as this code is deprecated and
211   * on track to be retired; use code 'HU' instead.
212   */
213  H_,
214  /**
215   * A test result that is significantly higher than the reference (normal) or
216   * therapeutic interval, but has not reached the critically high value and might
217   * need special attention, as defined by the laboratory or the clinician.
218   */
219  HU,
220  /**
221   * The result for a quantitative observation is below the lower limit of the
222   * reference range (as defined for the respective test procedure).
223   * 
224   * Synonym: Below low normal
225   */
226  L,
227  /**
228   * A test result that is significantly lower than the reference (normal) or
229   * therapeutic interval, but has not reached the critically low value and might
230   * need special attention, as defined by the laboratory or the clinician.[Note:
231   * This level is situated between 'L' and 'LL'.]
232   * 
233   * 
234   * Deprecation Comment: The code 'L<' is being deprecated in order to align with
235   * the use of the code 'LU' for "Very low" in V2 Table 0078 "Interpretation
236   * Codes".
237   * 
238   * [Note: The use of code 'L<' is non-preferred, as this code is deprecated and
239   * on track to be retired; use code 'LU' instead.
240   */
241  L_,
242  /**
243   * A test result that is significantly lower than the reference (normal) or
244   * therapeutic interval, but has not reached the critically low value and might
245   * need special attention, as defined by the laboratory or the clinician.
246   */
247  LU,
248  /**
249   * The result or observation value is within the reference range or expected
250   * norm (as defined for the respective test procedure).
251   * 
252   * [Note: Applies to numeric or non-numeric results.]
253   */
254  N,
255  /**
256   * Interpretations of anti-microbial susceptibility testing results
257   * (microbiology). At most one allowed.
258   */
259  _OBSERVATIONINTERPRETATIONSUSCEPTIBILITY,
260  /**
261   * Bacterial strain inhibited in vitro by a concentration of an antimicrobial
262   * agent that is associated with uncertain therapeutic effect. Reference: CLSI
263   * (http://www.clsi.org/Content/NavigationMenu/Resources/HarmonizedTerminologyDatabase/Harmonized_Terminolo.htm)
264   * Projects: ISO 20776-1, ISO 20776-2
265   * 
266   * [Note 1: Bacterial strains are categorized as intermediate by applying the
267   * appropriate breakpoints in a defined phenotypic test system.]
268   * 
269   * [Note 2: This class of susceptibility implies that an infection due to the
270   * isolate can be appropriately treated in body sites where the drugs are
271   * physiologically concentrated or when a high dosage of drug can be used.]
272   * 
273   * [Note 3: This class also indicates a "buffer zone," to prevent small,
274   * uncontrolled, technical factors from causing major discrepancies in
275   * interpretations.]
276   * 
277   * [Note 4: These breakpoints can be altered due to changes in circumstances
278   * (e.g., changes in commonly used drug dosages, emergence of new resistance
279   * mechanisms).]
280   */
281  I,
282  /**
283   * The patient is considered as carrier based on the testing results. A carrier
284   * is an individual who carries an altered form of a gene which can lead to
285   * having a child or offspring in future generations with a genetic disorder.
286   * 
287   * 
288   * 
289   * Deprecation Comment: This antimicrobial susceptibility test interpretation
290   * concept is recommended by OO to be deprecated as it is no longer recommended
291   * for use in susceptibility testing by CLSI (reference CLSI document M100-S22;
292   * Vol. 32 No.3; CLSI Performance Standards for Antimicrobial Susceptibility
293   * Testing; Twenty-Second Informational Supplement. Jan 2012).
294   */
295  MS,
296  /**
297   * Use when not enough clinical trial data published by the Clinical and
298   * Laboratory Standards Institutes (CLSI) is available to establish the
299   * breakpoints for susceptible / intermediate and resistant.
300   */
301  NCL,
302  /**
303   * A category used for isolates for which only a susceptible interpretive
304   * criterion has been designated because of the absence or rare occurrence of
305   * resistant strains. Isolates that have MICs above or zone diameters below the
306   * value indicated for the susceptible breakpoint should be reported as
307   * non-susceptible.
308   * 
309   * NOTE 1: An isolate that is interpreted as non-susceptible does not
310   * necessarily mean that the isolate has a resistance mechanism. It is possible
311   * that isolates with MICs above the susceptible breakpoint that lack resistance
312   * mechanisms may be encountered within the wild-type distribution subsequent to
313   * the time the susceptible-only breakpoint is set.
314   * 
315   * NOTE 2: For strains yielding results in the "nonsusceptible" category,
316   * organism identification and antimicrobial susceptibility test results should
317   * be confirmed.
318   * 
319   * Synonym: decreased susceptibility.
320   */
321  NS,
322  /**
323   * Bacterial strain inhibited in vitro by a concentration of an antimicrobial
324   * agent that is associated with a high likelihood of therapeutic failure.
325   * Reference: CLSI
326   * (http://www.clsi.org/Content/NavigationMenu/Resources/HarmonizedTerminologyDatabase/Harmonized_Terminolo.htm)
327   * Projects: ISO 20776-1, ISO 20776-2
328   * 
329   * [Note 1: Bacterial strains are categorized as resistant by applying the
330   * appropriate breakpoints in a defined phenotypic test system.]
331   * 
332   * [Note 2: This breakpoint can be altered due to changes in circumstances
333   * (e.g., changes in commonly used drug dosages, emergence of new resistance
334   * mechanisms).]
335   */
336  R,
337  /**
338   * A category for isolates where the bacteria (e.g. enterococci) are not
339   * susceptible in vitro to a combination therapy (e.g., high-level
340   * aminoglycoside and cell wall active agent). This is predictive that this
341   * combination therapy will not be effective.
342   * 
343   * 
344   * Usage Note: Since the use of penicillin or ampicillin alone often results in
345   * treatment failure of serious enterococcal or other bacterial infections,
346   * combination therapy is usually indicated to enhance bactericidal activity.
347   * The synergy between a cell wall active agent (such as penicillin, ampicillin,
348   * or vancomycin) and an aminoglycoside (such as gentamicin, kanamycin or
349   * streptomycin) is best predicted by screening for high-level bacterial
350   * resistance to the aminoglycoside.
351   * 
352   * 
353   * Open Issue: The print name of the code is very general and the description is
354   * very specific to a pair of classes of agents, which may lead to confusion of
355   * these concepts in the future should other synergies be found.
356   */
357  SYNR,
358  /**
359   * Bacterial strain inhibited by in vitro concentration of an antimicrobial
360   * agent that is associated with a high likelihood of therapeutic success.
361   * Reference: CLSI
362   * (http://www.clsi.org/Content/NavigationMenu/Resources/HarmonizedTerminologyDatabase/Harmonized_Terminolo.htm)
363   * Synonym (earlier term): Sensitive Projects: ISO 20776-1, ISO 20776-2
364   * 
365   * [Note 1: Bacterial strains are categorized as susceptible by applying the
366   * appropriate breakpoints in a defined phenotypic system.]
367   * 
368   * [Note 2: This breakpoint can be altered due to changes in circumstances
369   * (e.g., changes in commonly used drug dosages, emergence of new resistance
370   * mechanisms).]
371   */
372  S,
373  /**
374   * A category that includes isolates with antimicrobial agent minimum inhibitory
375   * concentrations (MICs) that approach usually attainable blood and tissue
376   * levels and for which response rates may be lower than for susceptible
377   * isolates.
378   * 
379   * Reference: CLSI document M44-A2 2009 "Method for antifungal disk diffusion
380   * susceptibility testing of yeasts; approved guideline - second edition" - page
381   * 2.
382   */
383  SDD,
384  /**
385   * A category for isolates where the bacteria (e.g. enterococci) are susceptible
386   * in vitro to a combination therapy (e.g., high-level aminoglycoside and cell
387   * wall active agent). This is predictive that this combination therapy will be
388   * effective.
389   * 
390   * 
391   * Usage Note: Since the use of penicillin or ampicillin alone often results in
392   * treatment failure of serious enterococcal or other bacterial infections,
393   * combination therapy is usually indicated to enhance bactericidal activity.
394   * The synergy between a cell wall active agent (such as penicillin, ampicillin,
395   * or vancomycin) and an aminoglycoside (such as gentamicin, kanamycin or
396   * streptomycin) is best predicted by screening for high-level bacterial
397   * resistance to the aminoglycoside.
398   * 
399   * 
400   * Open Issue: The print name of the code is very general and the description is
401   * very specific to a pair of classes of agents, which may lead to confusion of
402   * these concepts in the future should other synergies be found.
403   */
404  SYNS,
405  /**
406   * The patient is considered as carrier based on the testing results. A carrier
407   * is an individual who carries an altered form of a gene which can lead to
408   * having a child or offspring in future generations with a genetic disorder.
409   * 
410   * 
411   * 
412   * Deprecation Comment: This antimicrobial susceptibility test interpretation
413   * concept is recommended by OO to be deprecated as it is no longer recommended
414   * for use in susceptibility testing by CLSI (reference CLSI document M100-S22;
415   * Vol. 32 No.3; CLSI Performance Standards for Antimicrobial Susceptibility
416   * Testing; Twenty-Second Informational Supplement. Jan 2012).
417   */
418  VS,
419  /**
420   * The observation/test result is interpreted as being outside the inclusion
421   * range for a particular protocol within which the result is being reported.
422   * 
423   * 
424   * Example: A positive result on a Hepatitis screening test. Open Issue: EX, HX,
425   * LX: These three concepts do not seem to meet a clear need in the vocabulary,
426   * and their use in observation interpretation appears likely to be covered by
427   * other existing concepts (e.g., A, H, L). The only apparent significant
428   * difference is their reference to use in protocols for exclusion of study
429   * subjects. These concepts/codes were proposed by RCRIM for use in the
430   * CTLaboratory message. They were submitted and approved in the November 2005
431   * Harmonization cycle in proposal "030103C_VOCAB_RCRIM_l_quade_RCRIM Obs
432   * Interp_20051028154455". However, this proposal was not fully implemented in
433   * the vocabulary. The proposal recommended creation of the
434   * x_ClinicalResearchExclusion domain in ObservationInterpretation with a value
435   * set including those three concepts/codes, but there is no subdomain of that
436   * name or equivalent with a binding to either of the value sets that contain
437   * these concepts/codes. Members of the OO WG have recently attempted to contact
438   * members of RCRIM regarding these concepts, both by email and at the recent
439   * WGM in Atlanta, without response. It is felt by OO that the best course of
440   * action to take at this time is to add this comprehensive Open Issue rather
441   * than deprecate these three concepts at this time, until further discussion is
442   * held.
443   */
444  EX,
445  /**
446   * The observation/test result is interpreted as being outside the inclusion
447   * range for a particular protocol within which the result is being reported.
448   * 
449   * 
450   * Example: A positive result on a Hepatitis screening test. Open Issue: EX, HX,
451   * LX: These three concepts do not seem to meet a clear need in the vocabulary,
452   * and their use in observation interpretation appears likely to be covered by
453   * other existing concepts (e.g., A, H, L). The only apparent significant
454   * difference is their reference to use in protocols for exclusion of study
455   * subjects. These concepts/codes were proposed by RCRIM for use in the
456   * CTLaboratory message. They were submitted and approved in the November 2005
457   * Harmonization cycle in proposal "030103C_VOCAB_RCRIM_l_quade_RCRIM Obs
458   * Interp_20051028154455". However, this proposal was not fully implemented in
459   * the vocabulary. The proposal recommended creation of the
460   * x_ClinicalResearchExclusion domain in ObservationInterpretation with a value
461   * set including those three concepts/codes, but there is no subdomain of that
462   * name or equivalent with a binding to either of the value sets that contain
463   * these concepts/codes. Members of the OO WG have recently attempted to contact
464   * members of RCRIM regarding these concepts, both by email and at the recent
465   * WGM in Atlanta, without response. It is felt by OO that the best course of
466   * action to take at this time is to add this comprehensive Open Issue rather
467   * than deprecate these three concepts at this time, until further discussion is
468   * held.
469   */
470  HX,
471  /**
472   * The numeric observation/test result is interpreted as being below the low
473   * threshold value for a particular protocol within which the result is being
474   * reported.
475   * 
476   * Example: A Total White Blood Cell Count falling below a protocol-defined
477   * threshold value of 3000/mm^3 Open Issue: EX, HX, LX: These three concepts do
478   * not seem to meet a clear need in the vocabulary, and their use in observation
479   * interpretation appears likely to be covered by other existing concepts (e.g.,
480   * A, H, L). The only apparent significant difference is their reference to use
481   * in protocols for exclusion of study subjects. These concepts/codes were
482   * proposed by RCRIM for use in the CTLaboratory message. They were submitted
483   * and approved in the November 2005 Harmonization cycle in proposal
484   * "030103C_VOCAB_RCRIM_l_quade_RCRIM Obs Interp_20051028154455". However, this
485   * proposal was not fully implemented in the vocabulary. The proposal
486   * recommended creation of the x_ClinicalResearchExclusion domain in
487   * ObservationInterpretation with a value set including those three
488   * concepts/codes, but there is no subdomain of that name or equivalent with a
489   * binding to either of the value sets that contain these concepts/codes.
490   * Members of the OO WG have recently attempted to contact members of RCRIM
491   * regarding these concepts, both by email and at the recent WGM in Atlanta,
492   * without response. It is felt by OO that the best course of action to take at
493   * this time is to add this comprehensive Open Issue rather than deprecate these
494   * three concepts at this time, until further discussion is held.
495   */
496  LX,
497  /**
498   * Hold for Medical Review
499   * 
500   * 
501   * Usage Note: This code is not intended for use in V3 artifacts. It is included
502   * in the code system to maintain alignment with the V2 Table 0078
503   * "Interpretation Codes."
504   */
505  HM,
506  /**
507   * Interpretations of the presence or absence of a component / analyte or
508   * organism in a test or of a sign in a clinical observation. In keeping with
509   * laboratory data processing practice, these concepts provide a categorical
510   * interpretation of the "meaning" of the quantitative value for the same
511   * observation.
512   */
513  OBSERVATIONINTERPRETATIONDETECTION,
514  /**
515   * The specified component / analyte, organism or clinical sign could neither be
516   * declared positive / negative nor detected / not detected by the performed
517   * test or procedure.
518   * 
519   * 
520   * Usage Note: For example, if the specimen was degraded, poorly processed, or
521   * was missing the required anatomic structures, then "indeterminate" (i.e.
522   * "cannot be determined") is the appropriate response, not "equivocal".
523   */
524  IND,
525  /**
526   * The test or procedure was successfully performed, but the results are
527   * borderline and can neither be declared positive / negative nor detected / not
528   * detected according to the current established criteria.
529   */
530  E,
531  /**
532   * An absence finding of the specified component / analyte, organism or clinical
533   * sign based on the established threshold of the performed test or procedure.
534   * 
535   * [Note: Negative does not necessarily imply the complete absence of the
536   * specified item.]
537   */
538  NEG,
539  /**
540   * The presence of the specified component / analyte, organism or clinical sign
541   * could not be determined within the limit of detection of the performed test
542   * or procedure.
543   */
544  ND,
545  /**
546   * A presence finding of the specified component / analyte, organism or clinical
547   * sign based on the established threshold of the performed test or procedure.
548   */
549  POS,
550  /**
551   * The measurement of the specified component / analyte, organism or clinical
552   * sign above the limit of detection of the performed test or procedure.
553   */
554  DET,
555  /**
556   * Interpretation of the observed result taking into account additional
557   * information (contraindicators) about the patient's situation. Concepts in
558   * this category are mutually exclusive, i.e., at most one is allowed.
559   */
560  OBSERVATIONINTERPRETATIONEXPECTATION,
561  /**
562   * This result has been evaluated in light of known contraindicators. Once those
563   * contraindicators have been taken into account the result is determined to be
564   * "Expected" (e.g., presence of drugs in a patient that is taking prescription
565   * medication for pain management).
566   */
567  EXP,
568  /**
569   * This result has been evaluated in light of known contraindicators. Once those
570   * contraindicators have been taken into account the result is determined to be
571   * "Unexpected" (e.g., presence of non-prescribed drugs in a patient that is
572   * taking prescription medication for pain management).
573   */
574  UNE,
575  /**
576   * Interpretation qualifiers in separate OBX segments
577   * 
578   * 
579   * Usage Note: This code is not intended for use in V3 artifacts. It is included
580   * in the code system to maintain alignment with the V2 Table 0078
581   * "Interpretation Codes."
582   */
583  OBX,
584  /**
585   * Interpretations of the presence and level of reactivity of the specified
586   * component / analyte with the reagent in the performed laboratory test.
587   */
588  REACTIVITYOBSERVATIONINTERPRETATION,
589  /**
590   * An absence finding used to indicate that the specified component / analyte
591   * did not react measurably with the reagent.
592   */
593  NR,
594  /**
595   * A presence finding used to indicate that the specified component / analyte
596   * reacted with the reagent above the reliably measurable limit of the performed
597   * test.
598   */
599  RR,
600  /**
601   * A weighted presence finding used to indicate that the specified component /
602   * analyte reacted with the reagent, but below the reliably measurable limit of
603   * the performed test.
604   */
605  WR,
606  /**
607   * added to help the parsers
608   */
609  NULL;
610
611  public static V3ObservationInterpretation fromCode(String codeString) throws FHIRException {
612    if (codeString == null || "".equals(codeString))
613      return null;
614    if ("_GeneticObservationInterpretation".equals(codeString))
615      return _GENETICOBSERVATIONINTERPRETATION;
616    if ("CAR".equals(codeString))
617      return CAR;
618    if ("Carrier".equals(codeString))
619      return CARRIER;
620    if ("_ObservationInterpretationChange".equals(codeString))
621      return _OBSERVATIONINTERPRETATIONCHANGE;
622    if ("B".equals(codeString))
623      return B;
624    if ("D".equals(codeString))
625      return D;
626    if ("U".equals(codeString))
627      return U;
628    if ("W".equals(codeString))
629      return W;
630    if ("_ObservationInterpretationExceptions".equals(codeString))
631      return _OBSERVATIONINTERPRETATIONEXCEPTIONS;
632    if ("<".equals(codeString))
633      return LESS_THAN;
634    if (">".equals(codeString))
635      return GREATER_THAN;
636    if ("AC".equals(codeString))
637      return AC;
638    if ("IE".equals(codeString))
639      return IE;
640    if ("QCF".equals(codeString))
641      return QCF;
642    if ("TOX".equals(codeString))
643      return TOX;
644    if ("_ObservationInterpretationNormality".equals(codeString))
645      return _OBSERVATIONINTERPRETATIONNORMALITY;
646    if ("A".equals(codeString))
647      return A;
648    if ("AA".equals(codeString))
649      return AA;
650    if ("HH".equals(codeString))
651      return HH;
652    if ("LL".equals(codeString))
653      return LL;
654    if ("H".equals(codeString))
655      return H;
656    if ("H>".equals(codeString))
657      return H_;
658    if ("HU".equals(codeString))
659      return HU;
660    if ("L".equals(codeString))
661      return L;
662    if ("L<".equals(codeString))
663      return L_;
664    if ("LU".equals(codeString))
665      return LU;
666    if ("N".equals(codeString))
667      return N;
668    if ("_ObservationInterpretationSusceptibility".equals(codeString))
669      return _OBSERVATIONINTERPRETATIONSUSCEPTIBILITY;
670    if ("I".equals(codeString))
671      return I;
672    if ("MS".equals(codeString))
673      return MS;
674    if ("NCL".equals(codeString))
675      return NCL;
676    if ("NS".equals(codeString))
677      return NS;
678    if ("R".equals(codeString))
679      return R;
680    if ("SYN-R".equals(codeString))
681      return SYNR;
682    if ("S".equals(codeString))
683      return S;
684    if ("SDD".equals(codeString))
685      return SDD;
686    if ("SYN-S".equals(codeString))
687      return SYNS;
688    if ("VS".equals(codeString))
689      return VS;
690    if ("EX".equals(codeString))
691      return EX;
692    if ("HX".equals(codeString))
693      return HX;
694    if ("LX".equals(codeString))
695      return LX;
696    if ("HM".equals(codeString))
697      return HM;
698    if ("ObservationInterpretationDetection".equals(codeString))
699      return OBSERVATIONINTERPRETATIONDETECTION;
700    if ("IND".equals(codeString))
701      return IND;
702    if ("E".equals(codeString))
703      return E;
704    if ("NEG".equals(codeString))
705      return NEG;
706    if ("ND".equals(codeString))
707      return ND;
708    if ("POS".equals(codeString))
709      return POS;
710    if ("DET".equals(codeString))
711      return DET;
712    if ("ObservationInterpretationExpectation".equals(codeString))
713      return OBSERVATIONINTERPRETATIONEXPECTATION;
714    if ("EXP".equals(codeString))
715      return EXP;
716    if ("UNE".equals(codeString))
717      return UNE;
718    if ("OBX".equals(codeString))
719      return OBX;
720    if ("ReactivityObservationInterpretation".equals(codeString))
721      return REACTIVITYOBSERVATIONINTERPRETATION;
722    if ("NR".equals(codeString))
723      return NR;
724    if ("RR".equals(codeString))
725      return RR;
726    if ("WR".equals(codeString))
727      return WR;
728    throw new FHIRException("Unknown V3ObservationInterpretation code '" + codeString + "'");
729  }
730
731  public String toCode() {
732    switch (this) {
733    case _GENETICOBSERVATIONINTERPRETATION:
734      return "_GeneticObservationInterpretation";
735    case CAR:
736      return "CAR";
737    case CARRIER:
738      return "Carrier";
739    case _OBSERVATIONINTERPRETATIONCHANGE:
740      return "_ObservationInterpretationChange";
741    case B:
742      return "B";
743    case D:
744      return "D";
745    case U:
746      return "U";
747    case W:
748      return "W";
749    case _OBSERVATIONINTERPRETATIONEXCEPTIONS:
750      return "_ObservationInterpretationExceptions";
751    case LESS_THAN:
752      return "<";
753    case GREATER_THAN:
754      return ">";
755    case AC:
756      return "AC";
757    case IE:
758      return "IE";
759    case QCF:
760      return "QCF";
761    case TOX:
762      return "TOX";
763    case _OBSERVATIONINTERPRETATIONNORMALITY:
764      return "_ObservationInterpretationNormality";
765    case A:
766      return "A";
767    case AA:
768      return "AA";
769    case HH:
770      return "HH";
771    case LL:
772      return "LL";
773    case H:
774      return "H";
775    case H_:
776      return "H>";
777    case HU:
778      return "HU";
779    case L:
780      return "L";
781    case L_:
782      return "L<";
783    case LU:
784      return "LU";
785    case N:
786      return "N";
787    case _OBSERVATIONINTERPRETATIONSUSCEPTIBILITY:
788      return "_ObservationInterpretationSusceptibility";
789    case I:
790      return "I";
791    case MS:
792      return "MS";
793    case NCL:
794      return "NCL";
795    case NS:
796      return "NS";
797    case R:
798      return "R";
799    case SYNR:
800      return "SYN-R";
801    case S:
802      return "S";
803    case SDD:
804      return "SDD";
805    case SYNS:
806      return "SYN-S";
807    case VS:
808      return "VS";
809    case EX:
810      return "EX";
811    case HX:
812      return "HX";
813    case LX:
814      return "LX";
815    case HM:
816      return "HM";
817    case OBSERVATIONINTERPRETATIONDETECTION:
818      return "ObservationInterpretationDetection";
819    case IND:
820      return "IND";
821    case E:
822      return "E";
823    case NEG:
824      return "NEG";
825    case ND:
826      return "ND";
827    case POS:
828      return "POS";
829    case DET:
830      return "DET";
831    case OBSERVATIONINTERPRETATIONEXPECTATION:
832      return "ObservationInterpretationExpectation";
833    case EXP:
834      return "EXP";
835    case UNE:
836      return "UNE";
837    case OBX:
838      return "OBX";
839    case REACTIVITYOBSERVATIONINTERPRETATION:
840      return "ReactivityObservationInterpretation";
841    case NR:
842      return "NR";
843    case RR:
844      return "RR";
845    case WR:
846      return "WR";
847    case NULL:
848      return null;
849    default:
850      return "?";
851    }
852  }
853
854  public String getSystem() {
855    return "http://terminology.hl7.org/CodeSystem/v3-ObservationInterpretation";
856  }
857
858  public String getDefinition() {
859    switch (this) {
860    case _GENETICOBSERVATIONINTERPRETATION:
861      return "Codes that specify interpretation of genetic analysis, such as \"positive\", \"negative\", \"carrier\", \"responsive\", etc.";
862    case CAR:
863      return "The patient is considered as carrier based on the testing results. A carrier is an individual who carries an altered form of a gene which can lead to having a child or offspring in future generations with a genetic disorder.";
864    case CARRIER:
865      return "The patient is considered as carrier based on the testing results. A carrier is an individual who carries an altered form of a gene which can lead to having a child or offspring in future generations with a genetic disorder.\r\n\n                        \n                           \n                              Deprecation Comment: \n                           This code is currently the same string as the print name for this concept and is inconsistent with the conventions being used for the other codes in the coding system, as it is a full word with initial capitalization, rather than an all upper case mnemonic.  The recommendation from OO is to deprecate the code \"Carrier\" and to add \"CAR\" as the new active code representation for this concept.";
866    case _OBSERVATIONINTERPRETATIONCHANGE:
867      return "Interpretations of change of quantity and/or severity. At most one of B or W and one of U or D allowed.";
868    case B:
869      return "The current result or observation value has improved compared to the previous result or observation value (the change is significant as defined in the respective test procedure).\r\n\n                        [Note: This can be applied to quantitative or qualitative observations.]";
870    case D:
871      return "The current result has decreased from the previous result for a quantitative observation (the change is significant as defined in the respective test procedure).";
872    case U:
873      return "The current result has increased from the previous result for a quantitative observation (the change is significant as defined in the respective test procedure).";
874    case W:
875      return "The current result or observation value has degraded compared to the previous result or observation value (the change is significant as defined in the respective test procedure).\r\n\n                        [Note: This can be applied to quantitative or qualitative observations.]";
876    case _OBSERVATIONINTERPRETATIONEXCEPTIONS:
877      return "Technical exceptions resulting in the inability to provide an interpretation. At most one allowed. Does not imply normality or severity.";
878    case LESS_THAN:
879      return "The result is below the minimum detection limit (the test procedure or equipment is the limiting factor).\r\n\n                        Synonyms: Below analytical limit, low off scale.";
880    case GREATER_THAN:
881      return "The result is above the maximum quantifiable limit (the test procedure or equipment is the limiting factor).\r\n\n                        Synonyms: Above analytical limit, high off scale.";
882    case AC:
883      return "A valid result cannot be obtained for the specified component / analyte due to the presence of anti-complementary substances in the sample.\r\n\n                        \n                           \n                              Deprecation Comment: \n                           This code is being deprecated to match the status in V2 Table 0078 \"Interpretation Codes.";
884    case IE:
885      return "There is insufficient evidence that the species in question is a good target for therapy with the drug.  A categorical interpretation is not possible.\r\n\n                        [Note: A MIC with \"IE\" and/or a comment may be reported (without an accompanying S, I or R-categorization).]";
886    case QCF:
887      return "A result cannot be considered valid for the specified component / analyte or organism due to failure in the quality control testing component.\r\n\n                        \n                           \n                              Deprecation Comment: \n                           This code is being deprecated to match the status in V2 Table 0078 \"Interpretation Codes.";
888    case TOX:
889      return "A valid result cannot be obtained for the specified organism or cell line due to the presence of cytotoxic substances in the sample or culture.\r\n\n                        \n                           \n                              Deprecation Comment: \n                           This code is being deprecated to match the status in V2 Table 0078 \"Interpretation Codes.";
890    case _OBSERVATIONINTERPRETATIONNORMALITY:
891      return "Interpretation of normality or degree of abnormality (including critical or \"alert\" level). Concepts in this category are mutually exclusive, i.e., at most one is allowed.";
892    case A:
893      return "The result or observation value is outside the reference range or expected norm (as defined for the respective test procedure).\r\n\n                        [Note: Typically applies to non-numeric results.]";
894    case AA:
895      return "The result or observation value is outside a reference range or expected norm at a level at which immediate action should be considered for patient safety (as defined for the respective test procedure).\r\n\n                        [Note: Typically applies to non-numeric results.  Analogous to critical/panic limits for numeric results.]";
896    case HH:
897      return "The result for a quantitative observation is above a reference level at which immediate action should be considered for patient safety (as defined for the respective test procedure).\r\n\n                        Synonym: Above upper panic limits.";
898    case LL:
899      return "The result for a quantitative observation is below a reference level at which immediate action should be considered for patient safety (as defined for the respective test procedure).\r\n\n                        Synonym: Below lower panic limits.";
900    case H:
901      return "The result for a quantitative observation is above the upper limit of the reference range (as defined for the respective test procedure).\r\n\n                        Synonym: Above high normal";
902    case H_:
903      return "A test result that is significantly higher than the reference (normal) or therapeutic interval, but has not reached the critically high value and might need special attention, as defined by the laboratory or the clinician.[Note: This level is situated between 'H' and 'HH'.]\r\n\n                        \n                           Deprecation Comment: The code 'H>' is being deprecated in order to align with the use of the code 'HU' for \"Very high\" in V2 Table 0078 \"Interpretation Codes\".\r\n\n                        [Note: The use of code 'H>' is non-preferred, as this code is deprecated and on track to be retired; use code 'HU' instead.";
904    case HU:
905      return "A test result that is significantly higher than the reference (normal) or therapeutic interval, but has not reached the critically high value and might need special attention, as defined by the laboratory or the clinician.";
906    case L:
907      return "The result for a quantitative observation is below the lower limit of the reference range (as defined for the respective test procedure).\r\n\n                        Synonym: Below low normal";
908    case L_:
909      return "A test result that is significantly lower than the reference (normal) or therapeutic interval, but has not reached the critically low value and might need special attention, as defined by the laboratory or the clinician.[Note: This level is situated between 'L' and 'LL'.]\r\n\n                        \n                           Deprecation Comment: The code 'L<' is being deprecated in order to align with the use of the code 'LU' for \"Very low\" in V2 Table 0078 \"Interpretation Codes\".\r\n\n                        [Note: The use of code 'L<' is non-preferred, as this code is deprecated and on track to be retired; use code 'LU' instead.";
910    case LU:
911      return "A test result that is significantly lower than the reference (normal) or therapeutic interval, but has not reached the critically low value and might need special attention, as defined by the laboratory or the clinician.";
912    case N:
913      return "The result or observation value is within the reference range or expected norm (as defined for the respective test procedure).\r\n\n                        [Note: Applies to numeric or non-numeric results.]";
914    case _OBSERVATIONINTERPRETATIONSUSCEPTIBILITY:
915      return "Interpretations of anti-microbial susceptibility testing results (microbiology). At most one allowed.";
916    case I:
917      return "Bacterial strain inhibited in vitro by a concentration of an antimicrobial agent that is associated with uncertain therapeutic effect. Reference: CLSI (http://www.clsi.org/Content/NavigationMenu/Resources/HarmonizedTerminologyDatabase/Harmonized_Terminolo.htm)\nProjects: ISO 20776-1, ISO 20776-2\r\n\n                        [Note 1: Bacterial strains are categorized as intermediate by applying the appropriate breakpoints in a defined phenotypic test system.]\r\n\n                        [Note 2: This class of susceptibility implies that an infection due to the isolate can be appropriately treated in body sites where the drugs are physiologically concentrated or when a high dosage of drug can be used.]\r\n\n                        [Note 3: This class also indicates a \"buffer zone,\" to prevent small, uncontrolled, technical factors from causing major discrepancies in interpretations.]\r\n\n                        [Note 4: These breakpoints can be altered due to changes in circumstances (e.g., changes in commonly used drug dosages, emergence of new resistance mechanisms).]";
918    case MS:
919      return "The patient is considered as carrier based on the testing results. A carrier is an individual who carries an altered form of a gene which can lead to having a child or offspring in future generations with a genetic disorder.\r\n\n                        \n                           \n                              Deprecation Comment: \n                           This antimicrobial susceptibility test interpretation concept is recommended by OO to be deprecated as it is no longer recommended for use in susceptibility testing by CLSI (reference CLSI document M100-S22; Vol. 32 No.3; CLSI Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Second Informational Supplement. Jan 2012).";
920    case NCL:
921      return "Use when not enough clinical trial data published by the Clinical and Laboratory Standards Institutes (CLSI) is available to establish the breakpoints for susceptible / intermediate and resistant.";
922    case NS:
923      return "A category used for isolates for which only a susceptible interpretive criterion has been designated because of the absence or rare occurrence of resistant strains. Isolates that have MICs above or zone diameters below the value indicated for the susceptible breakpoint should be reported as non-susceptible.\r\n\n                        NOTE 1: An isolate that is interpreted as non-susceptible does not necessarily mean that the isolate has a resistance mechanism. It is possible that isolates with MICs above the susceptible breakpoint that lack resistance mechanisms may be encountered within the wild-type distribution subsequent to the time the susceptible-only breakpoint is set. \r\n\n                        NOTE 2: For strains yielding results in the \"nonsusceptible\" category, organism identification and antimicrobial susceptibility test results should be confirmed.\r\n\n                        Synonym: decreased susceptibility.";
924    case R:
925      return "Bacterial strain inhibited in vitro by a concentration of an antimicrobial agent that is associated with a high likelihood of therapeutic failure.\nReference: CLSI (http://www.clsi.org/Content/NavigationMenu/Resources/HarmonizedTerminologyDatabase/Harmonized_Terminolo.htm)  \nProjects: ISO 20776-1, ISO 20776-2\r\n\n                        [Note 1: Bacterial strains are categorized as resistant by applying the appropriate breakpoints in a defined phenotypic test system.]\r\n\n                        [Note 2: This breakpoint can be altered due to changes in circumstances (e.g., changes in commonly used drug dosages, emergence of new resistance mechanisms).]";
926    case SYNR:
927      return "A category for isolates where the bacteria (e.g. enterococci) are not susceptible in vitro to a combination therapy (e.g., high-level aminoglycoside and cell wall active agent).  This is predictive that this combination therapy will not be effective. \r\n\n                        \n                           Usage Note: Since the use of penicillin or ampicillin alone often results in treatment failure of serious enterococcal or other bacterial infections, combination therapy is usually indicated to enhance bactericidal activity. The synergy between a cell wall active agent (such as penicillin, ampicillin, or vancomycin) and an aminoglycoside (such as gentamicin, kanamycin or streptomycin) is best predicted by screening for high-level bacterial resistance to the aminoglycoside.\r\n\n                        \n                           Open Issue: The print name of the code is very general and the description is very specific to a pair of classes of agents, which may lead to confusion of these concepts in the future should other synergies be found.";
928    case S:
929      return "Bacterial strain inhibited by in vitro concentration of an antimicrobial agent that is associated with a high likelihood of therapeutic success.\nReference: CLSI (http://www.clsi.org/Content/NavigationMenu/Resources/HarmonizedTerminologyDatabase/Harmonized_Terminolo.htm)\nSynonym (earlier term): Sensitive Projects: ISO 20776-1, ISO 20776-2\r\n\n                        [Note 1: Bacterial strains are categorized as susceptible by applying the appropriate breakpoints in a defined phenotypic system.]\r\n\n                        [Note 2: This breakpoint can be altered due to changes in circumstances (e.g., changes in commonly used drug dosages, emergence of new resistance mechanisms).]";
930    case SDD:
931      return "A category that includes isolates with antimicrobial agent minimum inhibitory concentrations (MICs) that approach usually attainable blood and tissue levels and for which response rates may be lower than for susceptible isolates.\r\n\n                        Reference: CLSI document M44-A2 2009 \"Method for antifungal disk diffusion susceptibility testing of yeasts; approved guideline - second edition\" - page 2.";
932    case SYNS:
933      return "A category for isolates where the bacteria (e.g. enterococci) are susceptible in vitro to a combination therapy (e.g., high-level aminoglycoside and cell wall active agent).  This is predictive that this combination therapy will be effective. \r\n\n                        \n                           Usage Note: Since the use of penicillin or ampicillin alone often results in treatment failure of serious enterococcal or other bacterial infections, combination therapy is usually indicated to enhance bactericidal activity. The synergy between a cell wall active agent (such as penicillin, ampicillin, or vancomycin) and an aminoglycoside (such as gentamicin, kanamycin or streptomycin) is best predicted by screening for high-level bacterial resistance to the aminoglycoside.\r\n\n                        \n                           Open Issue: The print name of the code is very general and the description is very specific to a pair of classes of agents, which may lead to confusion of these concepts in the future should other synergies be found.";
934    case VS:
935      return "The patient is considered as carrier based on the testing results. A carrier is an individual who carries an altered form of a gene which can lead to having a child or offspring in future generations with a genetic disorder.\r\n\n                        \n                           \n                              Deprecation Comment: \n                           This antimicrobial susceptibility test interpretation concept is recommended by OO to be deprecated as it is no longer recommended for use in susceptibility testing by CLSI (reference CLSI document M100-S22; Vol. 32 No.3; CLSI Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Second Informational Supplement. Jan 2012).";
936    case EX:
937      return "The observation/test result is interpreted as being outside the inclusion range for a particular protocol within which the result is being reported.\n\r\n\n                        Example: A positive result on a Hepatitis screening test.\n                           Open Issue: EX, HX, LX: These three concepts do not seem to meet a clear need in the vocabulary, and their use in observation interpretation appears likely to be covered by other existing concepts (e.g., A, H, L).  The only apparent significant difference is their reference to use in protocols for exclusion of study subjects.\nThese concepts/codes were proposed by RCRIM for use in the CTLaboratory message.  They were submitted and approved in the November 2005 Harmonization cycle in proposal \"030103C_VOCAB_RCRIM_l_quade_RCRIM Obs Interp_20051028154455\".  However, this proposal was not fully implemented in the vocabulary.  The proposal recommended creation of the x_ClinicalResearchExclusion domain in ObservationInterpretation with a value set including those three concepts/codes, but there is no subdomain of that name or equivalent with a binding to either of the value sets that contain these concepts/codes.\nMembers of the OO WG have recently attempted to contact members of RCRIM regarding these concepts, both by email and at the recent WGM in Atlanta, without response.  It is felt by OO that the best course of action to take at this time is to add this comprehensive Open Issue rather than deprecate these three concepts at this time, until further discussion is held.";
938    case HX:
939      return "The observation/test result is interpreted as being outside the inclusion range for a particular protocol within which the result is being reported.\n\r\n\n                        Example: A positive result on a Hepatitis screening test.\n                           Open Issue: EX, HX, LX: These three concepts do not seem to meet a clear need in the vocabulary, and their use in observation interpretation appears likely to be covered by other existing concepts (e.g., A, H, L).  The only apparent significant difference is their reference to use in protocols for exclusion of study subjects.  These concepts/codes were proposed by RCRIM for use in the CTLaboratory message.  They were submitted and approved in the November 2005 Harmonization cycle in proposal \"030103C_VOCAB_RCRIM_l_quade_RCRIM Obs Interp_20051028154455\". However, this proposal was not fully implemented in the vocabulary.  The proposal recommended creation of the x_ClinicalResearchExclusion domain in ObservationInterpretation with a value set including those three concepts/codes, but there is no subdomain of that name or equivalent with a binding to either of the value sets that contain these concepts/codes.  Members of the OO WG have recently attempted to contact members of RCRIM regarding these concepts, both by email and at the recent WGM in Atlanta, without response.  It is felt by OO that the best course of action to take at this time is to add this comprehensive Open Issue rather than deprecate these three concepts at this time, until further discussion is held.";
940    case LX:
941      return "The numeric observation/test result is interpreted as being below the low threshold value for a particular protocol within which the result is being reported.\r\n\n                        Example: A Total White Blood Cell Count falling below a protocol-defined threshold value of 3000/mm^3\n                           Open Issue: EX, HX, LX: These three concepts do not seem to meet a clear need in the vocabulary, and their use in observation interpretation appears likely to be covered by other existing concepts (e.g., A, H, L).  The only apparent significant difference is their reference to use in protocols for exclusion of study subjects.  These concepts/codes were proposed by RCRIM for use in the CTLaboratory message.  They were submitted and approved in the November 2005 Harmonization cycle in proposal \"030103C_VOCAB_RCRIM_l_quade_RCRIM Obs Interp_20051028154455\".  However, this proposal was not fully implemented in the vocabulary.  The proposal recommended creation of the x_ClinicalResearchExclusion domain in ObservationInterpretation with a value set including those three concepts/codes, but there is no subdomain of that name or equivalent with a binding to either of the value sets that contain these concepts/codes.  Members of the OO WG have recently attempted to contact members of RCRIM regarding these concepts, both by email and at the recent WGM in Atlanta, without response.  It is felt by OO that the best course of action to take at this time is to add this comprehensive Open Issue rather than deprecate these three concepts at this time, until further discussion is held.";
942    case HM:
943      return "Hold for Medical Review\r\n\n                        \n                           Usage Note: This code is not intended for use in V3 artifacts.  It is included in the code system to maintain alignment with the V2 Table 0078 \"Interpretation Codes.\"";
944    case OBSERVATIONINTERPRETATIONDETECTION:
945      return "Interpretations of the presence or absence of a component / analyte or organism in a test or of a sign in a clinical observation. In keeping with laboratory data processing practice, these concepts provide a categorical interpretation of the \"meaning\" of the quantitative value for the same observation.";
946    case IND:
947      return "The specified component / analyte, organism or clinical sign could neither be declared positive / negative nor detected / not detected by the performed test or procedure.\r\n\n                        \n                           Usage Note: For example, if the specimen was degraded, poorly processed, or was missing the required anatomic structures, then \"indeterminate\" (i.e. \"cannot be determined\") is the appropriate response, not \"equivocal\".";
948    case E:
949      return "The test or procedure was successfully performed, but the results are borderline and can neither be declared positive / negative nor detected / not detected according to the current established criteria.";
950    case NEG:
951      return "An absence finding of the specified component / analyte, organism or clinical sign based on the established threshold of the performed test or procedure.\r\n\n                        [Note: Negative does not necessarily imply the complete absence of the specified item.]";
952    case ND:
953      return "The presence of the specified component / analyte, organism or clinical sign could not be determined within the limit of detection of the performed test or procedure.";
954    case POS:
955      return "A presence finding of the specified component / analyte, organism or clinical sign based on the established threshold of the performed test or procedure.";
956    case DET:
957      return "The measurement of the specified component / analyte, organism or clinical sign above the limit of detection of the performed test or procedure.";
958    case OBSERVATIONINTERPRETATIONEXPECTATION:
959      return "Interpretation of the observed result taking into account additional information (contraindicators) about the patient's situation. Concepts in this category are mutually exclusive, i.e., at most one is allowed.";
960    case EXP:
961      return "This result has been evaluated in light of known contraindicators.  Once those contraindicators have been taken into account the result is determined to be \"Expected\"  (e.g., presence of drugs in a patient that is taking prescription medication for pain management).";
962    case UNE:
963      return "This result has been evaluated in light of known contraindicators.  Once those contraindicators have been taken into account the result is determined to be \"Unexpected\" (e.g., presence of non-prescribed drugs in a patient that is taking prescription medication for pain management).";
964    case OBX:
965      return "Interpretation qualifiers in separate OBX segments\r\n\n                        \n                           Usage Note: This code is not intended for use in V3 artifacts.  It is included in the code system to maintain alignment with the V2 Table 0078 \"Interpretation Codes.\"";
966    case REACTIVITYOBSERVATIONINTERPRETATION:
967      return "Interpretations of the presence and level of reactivity of the specified component / analyte with the reagent in the performed laboratory test.";
968    case NR:
969      return "An absence finding used to indicate that the specified component / analyte did not react measurably with the reagent.";
970    case RR:
971      return "A presence finding used to indicate that the specified component / analyte reacted with the reagent above the reliably measurable limit of the performed test.";
972    case WR:
973      return "A weighted presence finding used to indicate that the specified component / analyte reacted with the reagent, but below the reliably measurable limit of the performed test.";
974    case NULL:
975      return null;
976    default:
977      return "?";
978    }
979  }
980
981  public String getDisplay() {
982    switch (this) {
983    case _GENETICOBSERVATIONINTERPRETATION:
984      return "GeneticObservationInterpretation";
985    case CAR:
986      return "Carrier";
987    case CARRIER:
988      return "Carrier";
989    case _OBSERVATIONINTERPRETATIONCHANGE:
990      return "ObservationInterpretationChange";
991    case B:
992      return "Better";
993    case D:
994      return "Significant change down";
995    case U:
996      return "Significant change up";
997    case W:
998      return "Worse";
999    case _OBSERVATIONINTERPRETATIONEXCEPTIONS:
1000      return "ObservationInterpretationExceptions";
1001    case LESS_THAN:
1002      return "Off scale low";
1003    case GREATER_THAN:
1004      return "Off scale high";
1005    case AC:
1006      return "Anti-complementary substances present";
1007    case IE:
1008      return "Insufficient evidence";
1009    case QCF:
1010      return "Quality control failure";
1011    case TOX:
1012      return "Cytotoxic substance present";
1013    case _OBSERVATIONINTERPRETATIONNORMALITY:
1014      return "ObservationInterpretationNormality";
1015    case A:
1016      return "Abnormal";
1017    case AA:
1018      return "Critical abnormal";
1019    case HH:
1020      return "Critical high";
1021    case LL:
1022      return "Critical low";
1023    case H:
1024      return "High";
1025    case H_:
1026      return "Significantly high";
1027    case HU:
1028      return "Significantly high";
1029    case L:
1030      return "Low";
1031    case L_:
1032      return "Significantly low";
1033    case LU:
1034      return "Significantly low";
1035    case N:
1036      return "Normal";
1037    case _OBSERVATIONINTERPRETATIONSUSCEPTIBILITY:
1038      return "ObservationInterpretationSusceptibility";
1039    case I:
1040      return "Intermediate";
1041    case MS:
1042      return "moderately susceptible";
1043    case NCL:
1044      return "No CLSI defined breakpoint";
1045    case NS:
1046      return "Non-susceptible";
1047    case R:
1048      return "Resistant";
1049    case SYNR:
1050      return "Synergy - resistant";
1051    case S:
1052      return "Susceptible";
1053    case SDD:
1054      return "Susceptible-dose dependent";
1055    case SYNS:
1056      return "Synergy - susceptible";
1057    case VS:
1058      return "very susceptible";
1059    case EX:
1060      return "outside threshold";
1061    case HX:
1062      return "above high threshold";
1063    case LX:
1064      return "below low threshold";
1065    case HM:
1066      return "Hold for Medical Review";
1067    case OBSERVATIONINTERPRETATIONDETECTION:
1068      return "ObservationInterpretationDetection";
1069    case IND:
1070      return "Indeterminate";
1071    case E:
1072      return "Equivocal";
1073    case NEG:
1074      return "Negative";
1075    case ND:
1076      return "Not detected";
1077    case POS:
1078      return "Positive";
1079    case DET:
1080      return "Detected";
1081    case OBSERVATIONINTERPRETATIONEXPECTATION:
1082      return "ObservationInterpretationExpectation";
1083    case EXP:
1084      return "Expected";
1085    case UNE:
1086      return "Unexpected";
1087    case OBX:
1088      return "Interpretation qualifiers in separate OBX segments";
1089    case REACTIVITYOBSERVATIONINTERPRETATION:
1090      return "ReactivityObservationInterpretation";
1091    case NR:
1092      return "Non-reactive";
1093    case RR:
1094      return "Reactive";
1095    case WR:
1096      return "Weakly reactive";
1097    case NULL:
1098      return null;
1099    default:
1100      return "?";
1101    }
1102  }
1103
1104}